[go: up one dir, main page]

MX2014011242A - Vacunas de conjugado carbohidrato-glicolipido. - Google Patents

Vacunas de conjugado carbohidrato-glicolipido.

Info

Publication number
MX2014011242A
MX2014011242A MX2014011242A MX2014011242A MX2014011242A MX 2014011242 A MX2014011242 A MX 2014011242A MX 2014011242 A MX2014011242 A MX 2014011242A MX 2014011242 A MX2014011242 A MX 2014011242A MX 2014011242 A MX2014011242 A MX 2014011242A
Authority
MX
Mexico
Prior art keywords
carbohydrate
vaccines
conjugate vaccines
vaccine
based vaccines
Prior art date
Application number
MX2014011242A
Other languages
English (en)
Other versions
MX337202B (es
Inventor
Peter H Seeberger
Pierre Stallforth
Gennaro De Libero
Marco Cavallari
Original Assignee
Max Planck Ges Zur Förderung Der Wissenschaften E V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/002277 external-priority patent/WO2013178236A1/en
Application filed by Max Planck Ges Zur Förderung Der Wissenschaften E V filed Critical Max Planck Ges Zur Förderung Der Wissenschaften E V
Publication of MX2014011242A publication Critical patent/MX2014011242A/es
Publication of MX337202B publication Critical patent/MX337202B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con el campo de la síntesis y evaluación biológica de una clase novedosa de vacunas basadas en carbohidratos. Las nuevas vacunas están compuestas por una estructura multimodular que permite la aplicación aplicar la vacuna a una completa variedad de patógenos. Este método permite la preparación de vacunas contra todos los patógenos que expresan antígenos carbohidrato inmunogénicos. Dado que no se requiere la conjugación de carbohidratos antigénicos a proteínas la vacuna de conjugado es particularmente estable térmicamente. No se requiere refrigeración, una desventaja principal de las vacunas basadas en proteínas.
MX2014011242A 2012-03-19 2013-03-19 Vacunas de conjugado carbohidrato-glicolipido. MX337202B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2012054848 2012-03-19
PCT/EP2012/002277 WO2013178236A1 (en) 2012-05-26 2012-05-26 Carbohydrate-glycolipid conjugate vaccines
PCT/EP2013/055719 WO2013139803A1 (en) 2012-03-19 2013-03-19 Carbohydrate-glycolipid conjugate vaccines

Publications (2)

Publication Number Publication Date
MX2014011242A true MX2014011242A (es) 2015-03-09
MX337202B MX337202B (es) 2016-02-17

Family

ID=47901120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011242A MX337202B (es) 2012-03-19 2013-03-19 Vacunas de conjugado carbohidrato-glicolipido.

Country Status (23)

Country Link
US (1) US10588962B2 (es)
EP (1) EP2827899B1 (es)
JP (2) JP5933106B2 (es)
KR (1) KR101675657B1 (es)
CN (1) CN104321079A (es)
AR (1) AR090386A1 (es)
AU (1) AU2013237497B2 (es)
BR (1) BR112014023193A2 (es)
CA (1) CA2866978C (es)
CY (1) CY1116706T1 (es)
DK (1) DK2827899T3 (es)
ES (1) ES2551599T3 (es)
HK (1) HK1205682A1 (es)
HU (1) HUE028144T2 (es)
IL (1) IL234604A (es)
MX (1) MX337202B (es)
PL (1) PL2827899T3 (es)
PT (1) PT2827899E (es)
RU (1) RU2649009C2 (es)
SG (1) SG11201405646TA (es)
SI (1) SI2827899T1 (es)
TW (1) TWI633112B (es)
WO (1) WO2013139803A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2851092A1 (en) * 2013-09-18 2015-03-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3
WO2016152980A1 (ja) * 2015-03-24 2016-09-29 国立大学法人岐阜大学 オリゴヌクレオチド誘導体及びそれを用いたオリゴヌクレオチド構築物並びにそれらの製造方法
CN106565800B (zh) * 2015-10-08 2019-08-13 中国人民解放军第二军医大学 三糖对甲氧基苯酚苷类化合物及其制备方法
TWI732825B (zh) * 2016-05-20 2021-07-11 日商王子控股股份有限公司 圖案形成用定向自組裝組成物、圖案形成用定向自組裝組成物用單體及圖案形成方法
CN106620682A (zh) * 2017-01-19 2017-05-10 华中师范大学 一种脂质体疫苗制剂及其用途和生产IgG抗体的方法
MX394767B (es) 2017-09-07 2025-03-24 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
CN107955082B (zh) * 2017-12-11 2019-05-10 江南大学 幽门螺旋杆菌脂多糖外核心八糖的制备方法
WO2021140203A1 (en) * 2020-01-10 2021-07-15 Universite De Nantes New immunostimulators and use thereof in immunotherapy
CN111760021B (zh) * 2020-05-18 2023-06-16 广州中医药大学(广州中医药研究院) 一种含有α-半乳糖神经酰胺类似物与糖抗原的缀合物及其制备方法和应用
CN111760020B (zh) * 2020-05-18 2023-05-26 广州中医药大学(广州中医药研究院) 一种缀合物及其制备方法和应用
WO2026010223A1 (ko) * 2024-07-01 2026-01-08 코스맥스에이비 주식회사 피부상재균을 이용한 극성지질 발효물의 제조방법 및 이를 포함하는 화장료 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
FI20010118L (fi) 2001-01-19 2002-07-20 Carbion Oy Uudet helicobacter pylori reseptorit ja niiden käyttö
CA2453880A1 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US8273357B2 (en) * 2004-07-16 2012-09-25 Massachusetts Institute Of Technology Antigen-carbohydrate conjugates
WO2006026389A2 (en) 2004-08-27 2006-03-09 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
US8022043B2 (en) 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
US7923013B2 (en) 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
WO2007051004A2 (en) * 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
ES2574825T3 (es) 2007-10-12 2016-06-22 Luigi Panza Análogos de glicolípidos útiles como inmunoadyuvantes
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
WO2010083728A1 (en) 2009-01-23 2010-07-29 Dapeng Zhou Nanoparticle formulated glycolipid antigens for immunotherapy
US8455565B2 (en) 2011-05-18 2013-06-04 3M Innovative Properties Company Disulfide monomers comprising ethylenically unsaturated groups suitable for dental compositions

Also Published As

Publication number Publication date
HUE028144T2 (en) 2016-11-28
PL2827899T3 (pl) 2015-12-31
IL234604A (en) 2016-03-31
TWI633112B (zh) 2018-08-21
ES2551599T3 (es) 2015-11-20
US10588962B2 (en) 2020-03-17
EP2827899A1 (en) 2015-01-28
HK1205682A1 (zh) 2015-12-24
MX337202B (es) 2016-02-17
SG11201405646TA (en) 2014-10-30
JP6235648B2 (ja) 2017-11-22
TW201343662A (zh) 2013-11-01
SI2827899T1 (sl) 2015-11-30
BR112014023193A2 (pt) 2017-08-01
KR101675657B1 (ko) 2016-11-11
US20150238597A1 (en) 2015-08-27
CA2866978A1 (en) 2013-09-26
RU2014142043A (ru) 2016-05-20
JP5933106B2 (ja) 2016-06-08
CN104321079A (zh) 2015-01-28
KR20140138996A (ko) 2014-12-04
AU2013237497A1 (en) 2014-10-02
JP2015514067A (ja) 2015-05-18
EP2827899B1 (en) 2015-08-05
CA2866978C (en) 2019-01-29
CY1116706T1 (el) 2017-03-15
WO2013139803A1 (en) 2013-09-26
AU2013237497B2 (en) 2016-05-12
AR090386A1 (es) 2014-11-05
DK2827899T3 (en) 2015-10-26
RU2649009C2 (ru) 2018-03-29
JP2016183166A (ja) 2016-10-20
PT2827899E (pt) 2015-11-18

Similar Documents

Publication Publication Date Title
MX2014011242A (es) Vacunas de conjugado carbohidrato-glicolipido.
EA201391240A1 (ru) Слитые белки и комбинированные вакцины, содержащие белок е и пилин а haemophilus influenza
CY1123769T1 (el) Νουκλεϊκα οξεα για την αγωγη αλλεργιων
CY1121789T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
EA201590705A1 (ru) ПОЛУЧЕНИЕ РЕКОМБИНАНТНОЙ ВАКЦИНЫ В E.coli ПОСРЕДСТВОМ ЭНЗИМАТИЧЕСКОЙ КОНЪЮГАЦИИ
MX2011011505A (es) Vacuna neumococica y usos de la misma.
EA201890942A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
NZ759686A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
MX358391B (es) Moleculas que son anticuerpos con especificidad por ox40 humano.
MX355501B (es) Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.
EA201391456A1 (ru) ВАКЦИНА ПРОТИВ Streptococcus pneumoniae
HK1207152A1 (en) Multivalent breast cancer vaccine
MX377803B (es) Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas.
WO2012047267A3 (en) Polyvalent immunogen
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
MX363149B (es) Vacunas de nucleoproteina de la influenza.
BR112013021870A2 (pt) vacina contra dengue tetravalente e bivalente mista
MX2015014005A (es) Complejo inmunogenico para vacunacion y metodo de obtencion.
WO2012103444A3 (en) Immunogenic compositions and reagents for preparing
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
MX374919B (es) ANTÍGENOS Y COMBINACIONES DE ANTÍGENOS PARA USARSE PARA ELEVAR LA RESPUESTA INMUNE CONTRA Haemophilus influenzae.
WO2013083753A3 (en) Identification of a swine parecho-like virus and applications

Legal Events

Date Code Title Description
FG Grant or registration